Latest Version of TrialAssure ANONYMIZE Released
TrialAssure has released its latest version of ANONYMIZE for Documents, including the functionality to anonymize and redact PDF documents concurrently.
TrialAssure ANONYMIZE for Documents is a document redaction and anonymization software that combines machine learning—a form of artificial intelligence—and natural language processing to protect patient privacy by automatically finding, masking, anonymizing, or removing personal or company confidential information from unstructured text.
“We are seeing a dramatic increase in the need for clinical trial sponsors to complete new and retrospective anonymization of clinical documents,” said Kelly Vaillant, Director of Global Transparency Strategy & Compliance, TrialAssure. “The impetus for document anonymization comes as increasing regulations from global health authorities and added pressure from advocacy groups push for the expanded utility of data for secondary research.”
To learn more, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
